136-150 of 883
Implementing the AMA MAP™ Hypertension Program: A Clinician's Experience
Perspectives with the AMAImplementing the AMA MAP™ Hypertension Program: A Clinician's Experience
Phase 3 study results of plozasiran in patients with FCS
CardiologyPhase 3 study results of plozasiran in patients with FCS
AI in Nuclear Medicine: Improvements in the Field
Project Oncology®AI in Nuclear Medicine: Improvements in the Field
Implementing a Successful Barostim Program in the Clinic: Best Practices and Real World Experience
CME/CEImplementing a Successful Barostim Program in the Clinic: Best Practices and Real World Experience
Beyond the Surface: The Impact of Psoriasis on Cardiovascular Health
Spotlight on PsoriasisBeyond the Surface: The Impact of Psoriasis on Cardiovascular Health
How Artificial Sweeteners Could Be Linked to Heart Disease
Heart MattersHow Artificial Sweeteners Could Be Linked to Heart Disease
- advertisement
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC Action CenterEffects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC Action CenterTargeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC Action CenterLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Promising results for self-expanding TAVR device in trial with mostly women
ACC Action CenterPromising results for self-expanding TAVR device in trial with mostly women
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC Action CenterAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Preventive PCI versus optimal medical therapy only for vulnerable plaques
ACC Action CenterPreventive PCI versus optimal medical therapy only for vulnerable plaques
- advertisement
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC Action CenterPromising results for APOC3 ASO in familial chylomicronemia syndrome
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC Action CenterIncreasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Self-assessment on statin eligibility without prescription using a web app
ACC Action CenterSelf-assessment on statin eligibility without prescription using a web app
